Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | CCR1 | P32246 | 3/20 | 0.54 |
| ▸ | CCR5 | P51681 | 3/20 | 0.54 |
| ▸ | CCR8 | P51685 | 3/20 | 0.54 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | METAP1 | P53582 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.52 |
| ▸ | NPC1 | O15118 | 6/20 | 0.52 |
| ▸ | HTT | P42858 | 5/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.52 |
| ▸ | TP53 | P04637 | 4/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31120747 | 1.00 | KDM4E (0.54) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL351473 | 0.85 | LOXL2 (0.46) | CCR1CCR5CCR8ADRB2CYP11B1 | |
| SCHEMBL7038028 | 0.81 | KDM4E (0.54) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL7035620 | 0.81 | KDM4E (0.54) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL1326112 | 0.81 | KDM4E (0.54) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL30471217 | 0.81 | KDM4E (0.54) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL149306 | 0.81 | KDM4E (0.54) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL18211344 | 0.80 | KDM4E (0.48) | KDM4ELMNACCR1CCR5CCR8 | |
| Hydrochloric Acid SCHEMBL7040410 | 0.79 | KDM4E (0.52) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL1720975 | 0.78 | CYP11B1 (0.59) | SMN1; SMN2NPC1RAB9AHPGDSCYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110563704-A | Tetrahedral cage assembled based on four-hydrogen bond and coordination bond synergistic effect and preparation method thereof | 南京工业大学 | 2019-12-13 | — | — | CN | claimed |
| US-12636366-B2 | Ruthenium (II) complexes and conjugates thereof for use as photosensitizer agent in photodynamic therapy | ECOLE NATIONALE SUPERIEURE DE CHIMIE DE PARIS (FR) | 2026-05-26 | — | — | US | disclosed |
| WO-2023140640-A1 | HETEROARYL DERIVATIVE AND USES THEREOF | 한양대학교 산학협력단 | 2023-07-27 | — | — | WO | disclosed |
| US-20220296711-A1 | Ruthenium (II) Complexes and Conjugates Thereof for Use as Photosensitizer Agent in Photodynamic Therapy | UNIVERSITY OF ZÜRICH (CH) | 2022-09-22 | — | — | US | disclosed |
| EP-3986904-A1 | RUTHENIUM (II) COMPLEXES AND CONJUGATES THEREOF FOR USE AS PHOTOSENSITIZER AGENT IN PHOTODYNAMIC THERAPY | Paris Sciences et Lettres (FR) | 2022-04-27 | — | — | EP | disclosed |
| EP-3757111-A1 | RUTHENIUM (II) COMPLEXES AND CONJUGATES THEREOF FOR USE AS PHOTOSENSITIZER AGENT IN PHOTODYNAMIC THERAPY | Paris Sciences et Lettres - Quartier Latin (FR) | 2020-12-30 | — | — | EP | disclosed |
| WO-2020260424-A1 | RUTHENIUM (II) COMPLEXES AND CONJUGATES THEREOF FOR USE AS PHOTOSENSITIZER AGENT IN PHOTODYNAMIC THERAPY | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2020-12-30 | — | — | WO | disclosed |
| CN-110563704-A | Tetrahedral cage assembled based on four-hydrogen bond and coordination bond synergistic effect and preparation method thereof | 南京工业大学 | 2019-12-13 | — | — | CN | disclosed |
| EP-2634178-B1 | QUINAZOLINE DERIVATIVE AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICATION OF TUMOR CELLS AND PREPARATION METHOD THEREOF | CHINESE ACAD INST CHEMISTRY (CN) | 2016-08-24 | — | — | EP | disclosed |
| US-9233995-B2 | Quinazoline derivatives and quinazoline complex protein kinase inhibitor for inhibiting multiplication of tumor cells and preparation method thereof | INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2016-01-12 | — | — | US | disclosed |
| US-9233995-B2 | Quinazoline derivatives and quinazoline complex protein kinase inhibitor for inhibiting multiplication of tumor cells and preparation method thereof | INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2016-01-12 | — | — | US | disclosed |
| US-20140066449-A1 | DIPYRIDINIUM DERIVATIVES | SABREPHARM LIMITED (GB) | 2014-03-06 | — | — | US | disclosed |
| EP-2680887-A1 | DIPYRIDINIUM DERIVATIVES | Sabrepharm Limited (GB) | 2014-01-08 | — | — | EP | disclosed |
| EP-2634178-A1 | QUINAZOLINE DERIVATIVE AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICATION OF TUMOR CELLS AND PREPARATION METHOD THEREOF | Institute Of Chemistry, Chinese Academy Of Sciences (CN) | 2013-09-04 | — | — | EP | disclosed |
| US-20130225811-A1 | QUINAZOLINE DERIVATIVES AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICAITON OF TUMOR CELLS AND PREPARATION METHOD THEREOF | INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCE (CN) | 2013-08-29 | — | — | US | disclosed |
| US-20130225811-A1 | QUINAZOLINE DERIVATIVES AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICAITON OF TUMOR CELLS AND PREPARATION METHOD THEREOF | INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCE (CN) | 2013-08-29 | — | — | US | disclosed |
| WO-2012117224-A1 | DIPYRIDINIUM DERIVATIVES | SABREPHARM LIMITED (GB) | 2012-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220296711-A1 | Ruthenium (II) Complexes and Conjugates Thereof for Use as Photosensitizer Agent in Photodynamic Therapy | ANXA5, CD47, SPR | KDM4E 4269/4885LMNA 4504/4885CCR1 3484/4885 |
| US-12636366-B2 | Ruthenium (II) complexes and conjugates thereof for use as photosensitizer agent in photodynamic therapy | FABP2, APC, TP53 | KDM4E 4759/4885LMNA 4746/4885CCR1 1967/4885 |
| US-20140066449-A1 | DIPYRIDINIUM DERIVATIVES | XDH, MKI67, ZFX | KDM4E 2211/4885LMNA 313/4885CCR1 1089/4885 |
| US-20130225811-A1 | QUINAZOLINE DERIVATIVES AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICAITON OF TUMOR CELLS AND PREPARATION METHOD THEREOF | MAP3K21, MAP3K15, MAP3K14 | KDM4E 1544/4885LMNA 2126/4885CCR1 2770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.